141 related articles for article (PubMed ID: 33860920)
1. Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Qian J; Truong CB; Tanni KA
BioDrugs; 2021 May; 35(3):375-377. PubMed ID: 33860920
[No Abstract] [Full Text] [Related]
2. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".
Putzke J; Haughie S; Zou KH; Ranganna GM
BioDrugs; 2021 May; 35(3):373-374. PubMed ID: 33860919
[No Abstract] [Full Text] [Related]
3. Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Tanni KA; Truong CB; Almahasis S; Qian J
BioDrugs; 2021 Mar; 35(2):239-254. PubMed ID: 33439472
[TBL] [Abstract][Full Text] [Related]
4. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States.
Xue X; Truong B; Qian J
Expert Opin Biol Ther; 2023; 23(8):841-849. PubMed ID: 36892184
[TBL] [Abstract][Full Text] [Related]
5. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P
Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
[TBL] [Abstract][Full Text] [Related]
6. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
7. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
Stergiopoulos S; Getz K
Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
[TBL] [Abstract][Full Text] [Related]
8. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
9. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
10. Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database.
Xue X; Qian J
Expert Opin Drug Saf; 2024 May; ():1-10. PubMed ID: 38680112
[TBL] [Abstract][Full Text] [Related]
11. Hypnotics and infections: disproportionality analysis of the U.S. Food & Drug Administration adverse event reporting system database.
Meng L; Huang J; He Q; Zhao Y; Zhao W; Tan J; Sun S; Yang J
J Clin Sleep Med; 2022 Sep; 18(9):2229-2235. PubMed ID: 35713182
[TBL] [Abstract][Full Text] [Related]
12. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
13. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
14. Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS).
Serebruany VL; Cherepanov V; Kim MH; Litvinov O; Cabrera-Fuentes HA; Marciniak TA
Cardiology; 2017; 138(4):249-253. PubMed ID: 28898876
[TBL] [Abstract][Full Text] [Related]
15. More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis.
Hauben M; Zou C; Bright S; Hung E
Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1140-1141. PubMed ID: 33960586
[No Abstract] [Full Text] [Related]
16. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
17. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
19. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
Zhang X; Hamadeh IS; Song S; Katz J; Moreb JS; Langaee TY; Lesko LJ; Gong Y
J Bone Miner Res; 2016 Feb; 31(2):336-40. PubMed ID: 26288087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]